Idiopathic Pulmonary Fibrosis (IPF)

Also known as: Idiopathic pulmonary fibrosis / Familial idiopathic pulmonary fibrosis / Cryptogenic fibrosing alveolitis

DrugDrug NameDrug Description
DB09079NintedanibNintedanib is a drug indicated for the treatment of idiopathic pulmonary fibrosis (IPF) that targets multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs). Nintedanib inhibits the following RTKs: platelet-derived growth factor receptor (PDGFR) α and β, fibroblast growth factor receptor (FGFR) 1-3, vascular endothelial growth factor receptor (VEGFR) 1-3, and Fms-like tyrosine kinase-3 (FLT3). Among them, FGFR, PDGFR, and VEGFR have been implicated in IPF pathogenesis. Nintedanib binds competitively to the adenosine triphosphate (ATP) binding pocket of these receptors and blocks the intracellular signaling which is crucial for the proliferation, migration, and transformation of fibroblasts representing essential mechanisms of the IPF pathology. In addition, nintedanib inhibits the following nRTKs: Lck, Lyn and Src kinases. The contribution of FLT3 and nRTK inhibition to IPF efficacy is unknown. Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal lung disease characterized by a progressive loss of lung function with worsening dyspnoea and cough. Development is thought to be instigated by repetitive lung injury (such as by cigarette smoke, industrial dusts, gastrooesophageal reflux and viral infection) leading to destruction of epithelial alveolar cells. Subsequent dysregulation of the repair process results in the proliferation/migration of fibroblasts and their differentiation into myofibroblasts, abnormal extracellular matrix deposition and excessive collagen accumulation in the lung interstitium and alveolar space, leading to progressive fibrosis and stiffening of the lungs. Vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) and platelet-derived growth factor (PDGF) mediate various processes, including fibrogenesis and angiogenesis, and are implicated in the pathogenesis of IPF. By blocking substrate binding and downstream signalling cascades, nintedanib interferes with processes active in fibrosis such as fibroblast proliferation, migration and differentiation, and the secretion of extracellular matrix.
DB00860PrednisoloneA glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]
DrugDrug NamePhaseStatusCount
DB01003Cromoglicic acid1Recruiting1
DB01254Dasatinib1Recruiting1
DB12396Fresolimumab1Completed1
DB04335Inosine1Active Not Recruiting1
DB12703Omipalisib1Completed1
DB04951Pirfenidone1Completed1
DB04216Quercetin1Recruiting1
DB01001Salbutamol1Completed1
DB12152Simtuzumab1Completed1
DB01610Valganciclovir1Not Yet Recruiting1
DB08828Vismodegib1Completed1
DB08804Nandrolone decanoate1 / 2Recruiting1
DB00104Octreotide1 / 2Completed1
DB12895TD-1391 / 2Completed1
DB05088Tiomolibdate ion1 / 2Completed1
DB06151Acetylcysteine2Completed1
DB00993Azathioprine2Completed1
DB00394Beclomethasone dipropionate2Completed1
DB11588Carbon monoxide2Active Not Recruiting1
DB00983Formoterol2Completed1
DB11914Lebrikizumab2Completed1
DB08932Macitentan2Completed1
DB08932Macitentan2Withdrawn1
DB09079Nintedanib2Completed1
DB00338Omeprazole2Completed1
DB04951Pirfenidone2Completed4
DB04951Pirfenidone2Recruiting1
DB04951Pirfenidone2Unknown Status1
DB00635Prednisone2Completed1
DB00073Rituximab2Withdrawn1
DB00203Sildenafil2Recruiting1
DB12152Simtuzumab2Terminated2
DB11798Tanzisertib2Terminated1
DB01041Thalidomide2Completed1
DB12435Tipelukast2Recruiting1
DB12169Tralokinumab2Completed1
DB12169Tralokinumab2Terminated1
DB00374Treprostinil2Terminated1
DB08828Vismodegib2Withdrawn1
DB00744Zileuton2Completed1
DB00559Bosentan2 / 3Completed1
DB00619Imatinib2 / 3Completed1
DB00678Losartan2 / 3Completed1
DB00203Sildenafil2 / 3Completed1
DB06403Ambrisentan3Terminated2
DB00559Bosentan3Completed2
DB00531Cyclophosphamide3Recruiting1
DB00898Ethanol3Recruiting1
DB00813Fentanyl3Recruiting1
DB00033Interferon gamma-1b3Terminated2
DB01017Minocycline3Unknown Status1
DB09079Nintedanib3Active Not Recruiting2
DB09079Nintedanib3Terminated1
DB04951Pirfenidone3Completed4
DB04951Pirfenidone3Recruiting1
DB00860Prednisolone3Recruiting1
DB00203Sildenafil3Active Not Recruiting1
DB01041Thalidomide3Completed1
DB05777Thrombomodulin Alfa3Recruiting1
DB00374Treprostinil3Unknown Status1
DB08604Triclosan3Recruiting1
DB00682Warfarin3Terminated1
DB00559Bosentan4Unknown Status2
DB09079Nintedanib4Active Not Recruiting1
DB09079Nintedanib4Completed3
DB04951Pirfenidone4Completed3
DB00203Sildenafil4Unknown Status2
DB00207AzithromycinNot AvailableRecruiting1
DB09079NintedanibNot AvailableActive Not Recruiting1
DB09079NintedanibNot AvailableNo Longer Available2
DB04951PirfenidoneNot AvailableApproved for Marketing1
DB04951PirfenidoneNot AvailableCompleted2
DB04951PirfenidoneNot AvailableRecruiting1
DB00877SirolimusNot AvailableActive Not Recruiting1